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Abstract. The relevance. The therapy of hypoxemic conditions by the substances, which are 
differing because of their key role in the vital processes of metabolism and also their high 
pharmacological activity, and which are known to be the regulators of redox systems, can be 
considered as one of the priority directions of the modern clinical and experimental 
pharmacology. Metal complexes of essential elements, which are the natural participants of the 
ligand formation, can be very interesting in this sense. The research goal. Experimental 
validation of the pharmacological correction of the hypoxic conditions of the N-alkenyl-, N-
propargylimidazoles and 3-hydroxypyridine metal complex derivatives. Test compounds and 
drugs. In comparison with well-known antihypoxants, antioxidants and actoprotectors in animal 
studies investigated acute toxicity, cytotoxicity, antihypoxic and actoprotective activity, effect on 
Central nervous system, liver, kidneys, heart, system of blood microcirculation, biochemical and 
hematological parameters, redox potential, studied the main ways of mechanism of action and the 
possibility of combined use with drugs of different pharmacological groups of complexes of zinc, 
cobalt, iron, derivatives of N-alkenyl-, N-propargylimidazol and 3-hydroxypiridine. The 
discussion of the results. The researched drugs are moderately and low toxic, so it proves their 
safety. The antyhypoxic and actoprotective effect has been shown by the complexes of cobalt 
(CoALL) and iron (tetravim) and also by the derivatives of N-alkenylimidazole. Hemostimulating 
effect of CoAll has also been  discovered. A possible mechanism of the antihypoxic effect of the 
test compounds could be attributed to the effect on coupling of oxidation and phosphorylation, 
maintenance of the mitochondria structure and functions in conditions of oxygen deficiency, 
elimination of the negative effect of hypoxia on carbohydrate metabolism, improvement of 
microcirculation and tissue oxygenation parameters and restore of the redox potential at hypoxia 
exposure. CoALL, probably, activates the key metabolism stages, which are responsible for 
energy supply by oxidizing organic substrates. The increasing of hematocrit, erythrocyte and 
hemoglobin levels can also be a protective factor of CoALL in condition of hypoxia. 
Conclusions. CoALL is promising for the further development as a hemostimulating drug, and 
CoALL and tetravim as antihypoxic and actoprotective drugs. Redox-regulating activity of metal 
complexes of the derivatives of N-alkenylimidazole offers the opportunities to construct new 
effective preparations of a wide spectrum of action on their basis. 
Keywords: antihypoxic activity, metal complex compounds, N-alkenylimidazoles, redox 
potential. 
 
Introduction. 
The urbanization of the modern world, the 
industrial growth, the introduction of chemical 
technologies in our national economy and our life, 
the appearance of high-toxic compounds, the 
accumulation of the toxins, the generation of 
genetically modified foods and also some ecological 
catastrophes can affect the environment and cause 
real threats to all of us [1-8]. 
The oxygen, which used to be one of the greatest 
vital necessities, has to compete with some chemical 
emissions, so its specific consumption decreases, 
which leads to hypoxic conditions. Oxygen 
deficiency can cause a lot of cellular metabolism 
violations, and, consequently, an inevitable death of 
the cell, causing serious pathologies. 
Oxygen insufficiency is one of the roots of the 
number of conditions:  cardiovascular, oncological, 
pulmonary, endocrine and other diseases [9-21].  
Hypoxic resistance increase has a great importance in 
military, marine, aviation and sport medicine, and 
also in the Emergency medicine [22-26]. 
The high-level capacity support during an acute 
hypoxia can be realized by antihypoxants. But their 
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diversity is very poor, their therapeutic effect is quite 
small, they can be useless for many types of hypoxia, 
and also they have a lot of side effects. That is why 
their application is limited. 
Modern principles of the pharmacological 
therapy include the conversion to the economical 
oxygen consumption mode, using circulatory 
dynamics regulators, calcium channel blockers, 
membrane stabilizers, antioxidants and antihypoxants 
[13, 14, 27]. But despite on that, the main reason of 
the hypoxic damage, such as reductive index 
increase, still remains. 
Unfortunately, complexes most of the modern 
drugs are presented by the different synthetic 
compounds of various compositions and are foreign for 
the human body. They are supposed to block certain 
biochemical processes and reach the therapeutic effect 
by the decrease of the organism’s adaptive response to 
the damage. But the lack of the target selectivity can 
drain the organism’s protective resource, up to its 
atrophy, so we can consider it as a great disadvantage. 
That is why, despite the rigorous selection of the new 
drugs, they all have a lot of side effects and also not 
very wide therapeutic effect, so it makes difficult to 
choose the right way of the therapy. 
All the listed disadvantages of the modern drugs 
occur because of their incompatibility with some 
biological systems. Every pathological process depends 
on 3 biological flows (metabolic, energetical and 
informational flow) regulated by endogenous redox 
(Red-Ox) controllers. Hypoxia causes the Red-Ox 
system imbalance, and the protective resource induction 
and mobilization are going through the activation of 
specific proteins. So, as far as the amino acid chain 
specific areas form the signal transduction structural 
mark, we can use the modified signal molecules of 
those proteins as a drug. These substances (different 
Red-Ox active signal molecules) could play a role of 
safe and highly effective drug. They could be based on 
some native participants of ligand-forming process in 
biological systems, such as amino acids, vitamins, 
polyphenols or bio elements. Any insignificant change 
of Red-Ox potential balance can influence the whole 
body functions, and this ligand-forming process 
maintains this balance. 
Based on the above mentioned, we have decided 
to choose the new way of the correction of the 
hypoxic conditions, based on the oxygen supply 
optimization and the simultaneous Red-Ox potential 
correction. The conception of the next-gen drug 
development could become a good alternative to 
replace the old-fashioned screening of the chemical 
substances [28].  
Besides, the searching of the new chemical 
substances with wide therapeutic effect and with a 
lack of any side effects is an important task for 
experimental and clinical pharmacology. 
So, the problem of finding and investigation of 
any effective and safe antihypoxants can be solved by 
the research, including the study of some chemical 
substances that play the key role in vital processes 
and which are known to be the Red-Ox systems 
regulators. 
We have tested 18 complexes of zinc, iron, 
cobalt and copper, based on N-alkenyl-,  
N-propargylimidazoles and 3-hydroxypyridine as 
those perspective compounds. These compounds had 
been synthesized in the laboratory of heteroatomic 
compounds of A.E. Favorsky Irkutsk Institute of 
Chemistry SB RAS under the direction of the 
Academician of RAS B.A. Trofimov. 
The research goal. Experimental validation of 
the pharmacological correction of the hypoxic 
conditions of the N-alkenyl-, N-propargylimidazoles 
and 3-hydroxypyridine metal complex derivatives. 
Test compounds and drugs. Depending on the 
type of the ligand we can divide N-alkenyl-,  
N-propargylimidazoles and 3-hydroxypyridine 
derivatives into 7 groups (table 1). 
The first group includes four vinylimidazole 
derivatives: acyzol, cobazol, tetravim and vim, 
containing zinc diacetate, cobalt dichloride, iron 
trichloride and iron diacetate, respectively. The second 
group is formed by two allenylimidazole derivatives: 
allim-1 and allim-2, which includes zinc diacetate. The 
third group consists of three isopropenylimidazole 
derivatives: pilim-1, pilim-2 and pilim-4, containing 
zinc diacetate, zinc diacetate and copper dichloride, 
respectively. The fourth group includes two 
allylimidazole derivatives: ALL and CoALL 
(containing zinc diacetate and cobalt dichloride, 
respectively); the fifth group contains complexes with 
zinc diacetate titled g-4, g-5, g-6, g-7 and g-8 
immobilized on sulfo-AG. The sixth and seventh 
groups include derivatives of N-propargylimidazole and 
3-hydroxypyridine, respectively. 
N-alkenylimidazole derivatives have the general 
formula (fig. 1): 
 
R – vinyl, allenyl, isopropyl or allyl; R1 – hydrogen or 
methyl; E – Zn(II), Fe(III), Co(II) or Cu(II); Ac – chloride 
or acetyl; n – 1, 2, 4. 
Figure 1. N-alkenylimidazole general formula 
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Table 1 
N-alkenyl-, N-propargylimidazoles and 3-hydroxypyridine metal complex derivatives 
№ Substance Chemical name of the substances 
I. N-vinylimidazole metal complex derivatives 
1 Acyzol bis(N-vinylimidazole) zinc diacetate 
2 Cobazol (tetravinylimidazole) cobalt dichloride 
3 Tetravim (tetravinylimidazole) iron trichloride 
4 Vim bis(N-vinylimidazole) iron diacetate 
II. N-allenylimidazole metal complex derivatives  
5 Аllim-1 bis(N-allenylimidazole) zinc diacetate  
6 Аllim-2 (N-allenyl-2-methylimidazole) zinc diacetate  
III. N-isopropenylimidazole metal complex derivatives  
7 Pilim-1 (N-isopropenylimidazole) zinc diacetate  
8 Pilim-2 (N-isopropenyl-2-methylimidazole) zinc diacetate  
9 Pilim-4 tetra(N-isopropenylimidazole) copper dichloride  
IV. N-allylimidazole metal complex derivatives  
10 АLL bis(N-allylimidazole) zinc diacetate 
11 CoALL bis (N-allylimidazole) cobalt dichloride 
V. Metal complex derivatives immobilized on sulfo-AG* 
12 g-4 Sulfo-АG*- bis(N-allenylimidazole) zinc diacetate  
13 g-5 Sulfo-АG*-(N- isopropenylimidazole) zinc diacetate  
14 g-6 Sulfo-АG*-(N-allenyl-2-methylimidazole) zinc diacetate  
15 g-7 Sulfo-АG*- bis(N- propargylimidazole) zinc diacetate  
16 g-8 Sulfo-АG*- bis(3-hydroxypyridine) zinc diacetate  
VI. 3-hydroxypyridine metal complex derivatives  
17 BIS-3 bis(3-hydroxypyridine) zinc diacetate  
VII. N-propargylimidazole metal complex derivatives  
18 BIS-N bis(N-propargylimidazole) zinc diacetate 
Notice. 
*
Sulfo-АG – sulfated arabinogalactan  
 
 
The modification of the imidazole cycle 
structure, deep research of its structure and the 
process of its coordination with metals are caused by 
the discovery of the specific pharmacological effect 
of complexes, depending on the metal nature, and the 
leading role of azole cycles in the pharmacy [29]. In 
light of the above, N-alkenylimidazole derivatives 
can be used as very perspective broad-spectrum 
drugs, particularly as antihypoxants. 
Nowadays, the original domestic drug 
«Acyzole» based on the N-alkenylimidazole 
derivatives was developed. It is the most potent 
antidote for carbon monoxide and the other 
combustion products in the world [30]. Also it can be 
a prophylactic and a cure for neurotoxins poisoning 
[31]. The drug decreases the toxic damage on the 
CNS, which results in long-term memory processes 
improvement, spontaneous motor activity and 
emotional behavior normalization.  
Acyzol decreases the intoxication severity 
during the carbon monoxide poisoning, and 
accelerates its elimination. It reduces the oxygen 
demand and increases the hypoxia resistance of the 
oxygen-sensitive organs (brain, myocardium, liver). 
Being a high effective antihypoxant, acyzole protects 
the organism, when the oxygen partial pressure is 
very low, and when hemoglobin oxygenation is 
lower, than it should be [32-34]. 
Besides, zinc, contained in acyzole, compensates 
its deficit in human body, helping to normalize 
metabolic processes, related to zinc-dependent 
enzymes. So, the drug could be used to treat any zinc 
deficiency conditions (Prasad disease, 
immunodeficiency, allergic dermatosis, prostate 
dysfunction etc.). Also, acyzole is established to be 
highly effective against psoriasis, one of the most 
common allergic dermatoses [35].  
Nowadays, acyzole anti-inflammatory, 
reparative, detoxifying, immunomodulatory, 
bacteriostatic, hepatoprotective, adaptogenic, 
antioxidant, cardioprotective and other functions 
have been discovered [36, 37]. The drug helps to 
protect respiratory, cardio-vascular and urinary 
systems function [38].  
Acyzole mechanism of action is known, and it is 
explained by its effect on hemoglobin subunit 
interaction. It comes together with Hill’s constant 
decrease, and Haldane’s effect removal. As a result, 
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CO affinity decreases, Douglas’s constant is getting 
lower and carbon monoxide elimination accelerates 
[34, 39].  
Acyzole increases hemoglobin affinity to the 
oxygen, oxygenated hemoglobin dissociation curve 
shifts to the left, increasing the vital organs 
oxygenation – brain, myocardium, liver. Also, 
acyzole, as universal energy exchange regulator, 
prevents the formation of highly reactive oxygen 
forms and balances Red-Ox processes in the cell [37]. 
Acyzole also has the membrane protective function, 
due to its antihypoxant and antioxidant effect [40].  
Cobazol (cobalt complex), is passing the clinical 
trials at this moment. It is a potent broad spectrum 
hematopoiesis stimulator. Cobazol is known to have 
erythropoietic and leucopoetic activity, 
immunomodulatory and antibacterial functions. Its 
activity surpasses one of the iron-containing drugs – 
B12 vitamin and leucogen [41]. It also has the 
antibacterial activity, exceeding streptomycin and 
tetracycline one in 2–3 times [42]. Cobazole 
immunomodulatory functions, caused by the 
increasing of the number of lymphocytes and 
neutrophil phagocytic function, significantly expand 
its medical value [42]. 
The drug is very effective against different types 
of anemia: post-hemorrhagic, hypochromic, 
hemolytic, including the iron-containing drug 
resistant types and radiation-induced types. It 
prevents cytotoxic and post radial leucopenia, so it 
makes antineoplastic chemotherapy and radial 
therapy safer and more effective. Compared with 
ferroplex and ferrum-lek, cobasole causes faster 
increase of hemoglobin [43]. Cobazole effects make 
it indispensable for oncological diseases and 
emergency medicine.  
3-hydroxypiridine derivatives are the 
perspective chemical compounds for the investigation 
during the different extreme factors influence [44]. 
Zinc, cobalt, iron and copper, contained in the 
studied complexes, are ecologically valuable and 
vital for human body, which confirms their 
essentiality. 
Chemically pure nooglutyl and etomerzole, 
bemythil (metaprot, actoprotector, «Pharmproekt», 
Russia), bromantan (ladasten, psychostimulant with 
an actoprotective effect, «Lekko», Russia), mexidol 
(«Pharmasoft», Russia) and hypoxen («Olifen corp.», 
Russia) were taken as comparison drugs. 
Synergistic action of the N-alkenylimidazole 
derivatives was studied using commonly used in 
clinic drugs referred to different pharmacological 
classes: metaprot, mexidol, aktovegin, inosine, 
pikamilon, acetylsalicylic acid (ASA). 
The investigated compounds and drugs were 
dissolved in water for injections or in Twin-80 
emulsifier («V.A.G. Chemie», Germany), in 
concentration of 0,1–12%. They were once given 
intraperitoneally (i/р) or intragastric (i/g), 1 or 3 hours, 
respectively, before the selected indicators registration 
or the extreme factor effect. Metal complex compounds 
were given in different doses: from ineffective to toxic. 
The drugs were given in doses, which could be effective 
for different pathologies, according to the literature. The 
control group was treated with the equal volume of the 
solvent. 
Research methods. In accordance with goals 
and objectives of the study, the experiments were 
conducted on 9877 white, outbread male mice 18–25 
g, 192 white, outbred male rats 110–130 g and on 18 
nonlinear male rabbits of the chinchilla breed 2.0–2.5 
kg. The animals had been kept on a regular diet with 
an unlimited access to drinking water, according to 
the group accommodation rules (+18–20 ˚C, 40–70% 
relative humidity, native light).  
The experiments were performed according to the 
following articles: The 11th article of The Helsinki 
declaration that had been accepted by the World 
Medical Association in 1964, The rules of the European 
Convention for the Protection of Vertebral Animals that 
are used for scientific research (ETS 123, Strasbourg, 
1986) – GLP (decree 708n by the Ministry of Health of 
Russia, 23.08.2010), The manual of the conduction of 
preclinical trials of drugs (2012) [45]. 
 The acute toxicity of the studied chemical 
compounds were studied on white male mice at a 
single i/p or i/g injection of aqueous solutions. The 
animal’s death was registered every 24 hours. The 
supervision was being provided during 2 weeks. On 
the 7th and the 14th days the weight of survived 
animals was measured. On the 15th day these mice 
were euthanized with an overdose of ester. After all, 
the vital organs were weighted and all the 
pathomorphological changes were observed. The 
acute toxicity indexes (LD16, LD50, LD84) were 
graphically calculated following the method of Miller 
and Tainter [46, 47] and estimated according to 4 
grades of danger according to the National Standard 
12.1.007-76 [48].  
Cytotoxicity against MDCK cells (dog’s kidney) 
and Vero cells (green monkey’s embryonic kidney) 
was measured with MTT assay, characterizing 
cellular respiration intensity. The estimation of MTT-
assay results was made by cytotoxic index (IC) 
calculation according to the following formula:  
 
IC = (К – О) х 100%, 
К 
 
K – optical density in the control wells;  O – 
optical density in the studied wells.  
Antihypoxic activity was studied in 4 models of 
acute hypoxia: hypobaric (AHBH), hypoxia with 
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hypercapnia (AHwHc), hemic (AHeH) and histotoxic 
(AHtH) [49, 50].  
Mice physical performance in regular conditions 
was estimated according to the duration of the run on 
a 6-track treadmill which was set on a standard 
treadmill [50-53]. Besides that, it was estimated by 
measuring the duration of the swim in a swimming 
pool (+28º С) with a weight fixed to the beginning of 
tail which is equal to 7% of mouse’s weight. Mice 
physical performance in case of AHBH was 
determined by measuring the duration of the run on a 
2-track treadmill, put into an electrovacuum furnace. 
The altitude of the lift was 7500 m, the speed of the 
conveyer belt equaled 15–16 m/min, the speed of 
lifting – 50 m/sec [53]. Mice physical performance in 
case of AHwHc was studied according to the 
swimming trial in a can of transparent glass [53].  
The functional status of the CNS of the animals 
was studied with 3 tests: conditioned protective reflex 
of avoidance (CPRA), anticonvulsant activity in case 
of subcutaneous introduction of corazol (125 mg/kg), 
and individual behavior in «open space» [54, 55].  
To measure the functional status of animal liver 
on CLIMA MC-15 analyzer (RAL, Spain) the 
following biochemical indexes had been measured: 
total protein, albumins, globulins, total and 
conjugated bilirubin, cholesterol, triglycerides, 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT). The blood was taken from 
neck blood vessels of the decapitated mice. Mice 
liver detox function was estimated by measuring the 
duration of their hexenal sleep after subcutaneous 
introduction (back derma) of 0.6% solution of 
hexenal (60 mg/kg) [56]. Liver carbohydrate 
metabolism was evaluated by the glucose blood level 
measurement after galactose loading test with the 
dosage 1 g/kg [57]. 
The kidney functional status was defined by the 
estimation of diuretic and nitrogen excretory 
functions, urine pH and density. The measurement 
was carried out with CLIMA MC-15 biochemichal 
analyzer (RAL, Spain).  
Unanesthetized animal electrocardiographic 
indexes were registered with RM-6000 polygraph 
(Japan).  
The mice oxidative exchange intensity was 
estimated according to their oxygen consumption 
index and their rectal temperature. Oxygen 
consumption was determined with S.D. Miropolky’s 
closed-type apparatus during 9–12 min after 
preliminary 10 minute adaptation in the respiratory 
camera [50].  
Glucose level in the blood serum of the 
decapitated mice was registered with CLIMA MC-15 
biochemical analyzer (RAL, Spain).  
Blood morphological indexes, hemoglobin and 
hematocrit level were determined with Exell  
18-optioned automatic hematological apparatus 
(Drew, Netherlands). The blood was taken from neck 
blood vessels of the decapitated mice.  
The options of microcirculatory dynamics and 
blood oxygenation in microcirculatory system were 
estimated using the laser doppler flowmetry (LDF) 
and tissue optical oximetry (TOO) at the same time. 
The measurements were provided with «LAKK-M» 
multifunctional laser diagnostic complex (Lazma, 
Russia). The capillary blood flow was measured on 
the external surface of the animal hind limbs.  
For the Red-Ox potential calculation we used the 
fluorescent oxygen consumption index (FOCI) of the 
enzymes that take part in the respiratory chain and 
which is inversely proportional to the Red-Ox ratio:  
FOCI = ANADH/AFAD 
ANADH – the amplitude of the fluorescent 
emission of the reduced nicotinamide adenine 
dinucleotide. AFAD – the amplitude of the fluorescent 
emission of the oxygenated flavoproteins (FAD) [58]. 
The obtained dimensionless parameter reflects 
mitochondrial activity level and doesn’t depend on 
apparatus factors or object dispersion properties.  
The statistical treatment of the data was made 
with the computer program Microsoft Excel XP, 
based on Windows XP and STATISTICA 6.0. For 
the variational series of the sample, the average value 
(M), and its error (m) were calculated. The normality 
of the sample was tested with Shapiro-Wilk test. As 
all the samples had the distribution, which is close to 
the normal one, the significance of the differences 
between experimental groups was determined with 
one-dimensional dispersive analysis with the further 
treatment with Student’s multiple comparisons 
method, using the Bonferron. 
Discussion of the results. 
Acute toxicity evaluation of N-alkenyl-, N-
propargylimidazoles and 3-hydroxypyridine metal 
complex derivatives and analysis of the results, 
considering State Standard’s requirements 
№12.1.007-76 [48] showed us, that tetravim is a low 
toxic compound (LD50 at intraperitoneal injection 
1625 mg/kg), and pilim-4 is a high toxic compound 
(10 mg/kg accuses mice death). The rest of 
substances are moderately toxic (LD50 is in the range 
from 40 to 1250 mg/kg.) For CoALL and tetravim, 
which are the most effective for hypoxic conditions, 
LD50 were 500 mg/ kg (CoALL, i/g) and 2100 mg/kg 
(tetravim, i/g). 
As we can see on fig. 2, tetravim concentration, 
inhibiting dehydrogenase metabolic activity (IC50) is 
approximately 250 mg/kg for MDCK cell lines, and 
more than 2000 mg/kg for Vero. 
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Table 2 
Effect of N-alkenyl-, N-propargylimidazoles, 3-hydroxypyridine metal complex derivatives and comparison drugs on the mice lifespan during acute hypoxia 
 
Substance, drug 
Hypoxic 
model 
Dose, mg/kg, i/p  
1 5 10 25 50 100 150 200 250 
I. N-vinylimidazole metal complex derivatives   
Cobazol AHBH - 113±7 138±6* 154±12* 200±10* 238±8* 133±7* - - 
Acyzol AHBH - 95±6 216±14* 276±18* 222±9* 162±12* 111±8 - - 
Tetravim AHBH 114±9 154±5* 227±5* 182±5* 190±6* 187±9* 197±6* 207±6* 200±9* 
Vim AHBH 115±8 158±6* 153±7* 144±6* 150±8* 193±5* 175±6* - - 
Cobazol AHwHc - - 99±4 122±5* 139±6* 154±4* 152±4* - - 
Acyzol AHwHc - - 103±4 138±7* 199±4* 174±4* 180±2* - - 
Tetravim AHwHc - - 109±3 106±4 197±7* 175±6* 150±5* 145±3* 142±4* 
Vim AHwHc - - 111±5 114±7 159±7* 158±3* 154±5* 161±2* - 
Cobazol AHeH - - - 97±3 134±7* 157±5* 117±7 - - 
Acyzol AHeH - - - 114±12 161±11* 192±6* 166±10* - - 
Тetravim AHeH - - - 113±4 123±5* 137±3* 131±9* 126±3* 126±5* 
Vim AHeH - - - 98±11 94±10 105±6 - - - 
Cobazol AHtH - - 94±10 130±5* 140±7* 166±4* 244±4* - - 
Acyzol AHtH - - - 98±9 109±10 - - - - 
Теtravim AHtH 107±13 131±7* 135±6* 131±6* 136±8* 121±5* 129±8* 125±6* 129±8* 
Vim AHtH - - - 97±9 99±7 92±8 - - - 
II. N-allenylimidazole metal complex derivatives   
Аllim-1 AHBH - 112±15 179±6* 188±7* 159±6* 108±13 - - - 
Аllim-2 AHBH - 96±10 143±5* 168±8* 191±7* 117±11 - - - 
Аllim-1 AHwHc - 103±2 122±4* 123±2* 154±4* - - - - 
Аllim-2 AHwHc - 101±9 118±5 121±5* 153±5* - - - - 
Аllim-1 AHeH - - - 95±10 99±5 128±7* - - - 
Аllim-2 AHeH - - 95±5 112±13 147±5* 98±9 - - - 
Аllim-1 AHtH - - - 84±11 95±13 125±6* - - - 
Аllim-2 AHtH - - - 90±12 85±8 135±8* - - - 
III. N-isopropenylimidazole metal complex derivatives   
Pilim-1 AHBH 110±9 127±3* 184±6* 169±3* 135±5* 98±22 - - - 
Pilim-2 AHBH 107±15 129±5* 181±6* 190±7* 175±4* 129±6* 108±16 - - 
Pilim-1 AHwHc - - 103±5 143±6* 204±8* - - - - 
Pilim-2 AHwHc - 98±6 98±4 120±5* 155±6* - - - - 
Table 2 
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Table 2 (continueed) 
 
Substance, drug 
Hypoxic 
model 
Dose, mg/kg, i/p 
1 5 10 25 50 100 150 200 250 
Pilim-1 AHeH - - 106±6 135±9* 169±10* 141±4* - - - 
Pilim-2 AHeH - - - 99±6 109±5 - - - - 
Pilim-1 AHtH - - - 84±8* 83±6* - - - - 
Pilim-2 AHtH - - - 73±4* 74±5* - - - - 
IV. N-allylimidazole metal complex derivatives   
АLL AHBH - 114±14 159±5* 189±10* 228±5* 225±5* - - - 
CoALL AHBH - 118±17 133±7* 254±13* 281±15* 263±15* - - - 
АLL AHwHc 107±7 108±6 127±4* 131±7* 183±10* 191±11* - - - 
CoALL AHwHc - - 117±5* 118±2* 138±7* 136±8* - - - 
АLL AHeH - -   94±4 94±9 109±4 108±6 - - - 
CoALL AHeH - 105±6 151±8* 135±7* 155±5* 187±4* - - - 
АLL AHtH - - 108±5 93±10 92±6 94±7 - - - 
CoALL AHtH - 108±6 119±5* 139±6* 175±5* 180±5* - - - 
V. Metal complex derivatives immobilized on sulfo-AG   
g-4 AHBH - - 104±22 117±18 116±15 100±21 - - - 
g-5 AHBH - - 116±16 104±27 106±20 106±22 - - - 
g-6 AHBH - - 113±19 95±21 115±15 100±22    
g-7 AHBH - - - 92±9 92±4 - - - - 
g-8 AHBH - - - 100±9 98±9 - - - - 
g-4 AHwHc - - 97±4 100±3 112±2 102±8 - - - 
g-5 AHwHc - - 99±4 98±6 102±5 116±9 - - - 
g-6 AHwHc - - 93±2 103±6 101±8 108±9 - - - 
g-7 AHwHc - - - 93±8 108±12 - - - - 
g-8 AHwHc - - - 81±6 105±12 - - - - 
g-4 AHeH - - 119±3* 109±11 103±4 103±10 - - - 
g-5 AHeH - - 110±5 117±5 - - - - - 
g-6 AHeH - - 115±4 111±3 - - - - - 
g-7 AHeH - - 95±6 98±8 - - - - - 
g-8 AHeH - - 95±8 96±5 - - - - - 
g-4 AHtH - - 107±5 115±9 - - - - - 
g-5 AHtH - - 107±8 116±7 - - - - - 
g-6 AHtH - - 139±7* 108±5 - - - - - 
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Table 2 (continueed) 
 
Substance, drug 
Hypoxic 
model 
Dose, mg/kg, i/p 
1 5 10 25 50 100 150 200 250 
g-7 AHtH - - 109±8 98±10 - - - - - 
g-8 AHtH - - 106±9    109±7 - - - - - 
VI. 3-hydroxypyridine metal complex derivatives  
BIS-3 AHBH - - 82±18 235±12* 267±13* 212±8* - - - 
BIS-3 AHwHc - - 115±4 127±3* 130±4* 185±4* - - - 
BIS-3 AHeH - - - 108±4 113±6 - - - - 
BIS-3 AHtH - - - 99±7 95±4 - - - - 
VII. N-propargylimidazole metal complex derivatives   
BIS-N AHBH 177±9* 191±6* 262±5* 293±7* 417±10* 267±5* - - - 
BIS-N AHwHc - 93±4 131±6* 155±6* 193±2* 103±3 - - - 
BIS-N AHeH - - 119±4* 125±5* 135±3* 121±6* - - - 
BIS-N AHtH - - - 117±9 118±4 - - - - 
VIII. Сomparison drugs  
Etomerzol AHBH - - - 98±10 108±11 157±9* - - - 
Mexidol  AHBH - - - 94±11 90±16 91±19 - - - 
Nooglutyl  AHBH - - - 174±8* 134±8* 137±7* - - - 
Hypoxen  AHBH - - - 110±5 244±9* 251±7* 267±8* - - 
Etomerzol AHwHc - - - 96±8 96±9 132±3* - - - 
Mexidol  AHwHc - - - 92±6 104±7 123±5* - - - 
Nooglutyl  AHwHc - - - 119±4* 126±4* 138±4* - - - 
Hypoxen  AHwHc - - - - 97±5 126±4* 129±4* - - 
Etomerzol AHeH - - - 125±7* 143±4* 106±8  - - 
Mexidol  AHeH - - - 94±9 99±5 114±2*  - - 
Nooglutyl  AHeH - - - 116±3* 130±5* 123±5*  - - 
Hypoxen  AHeH - - - - - 112±2* 121±2* - - 
Etomerzol AHtH - - - 114±4* 106±5 94±7 - - - 
Mexidol  AHtH - - - 106±9 106±7 108±9 - - - 
Nooglutyl  AHtH - - - 107±5 106±3 120±3* - - - 
Hypoxen  AHtH - - - 104±4 143±3* 189±6* 119±3* - - 
 
Notice.* – Significant differences compared with control animals at p < 0.05. Data are expressed as M ± m. M – arithmetic mean as % relative to the control group (100%); m – standard 
error of the mean as % relative to the arithmetic mean.
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Figure 2. Cytotoxic effect of tetravim on MDCK and Vero cell cultures 
 
Body mass’ observation, data about autopsy and 
macroscopic study of internal organs of euthanized 
animals, which had survived after an injection of 
tetravim and CoALL, haven’t revealed any statistic 
meaningful changes, comparing with the control group. 
Antihypoxic activity of the researched  
N-alkenyl-, N-propargylimidazoles and  
3-hydroxypyridine derivatives (i/p and i/g injections) 
was studied on 6130 mice. The results of the 
experiments show, that the researched metal 
complexes differently affect mice lifespan in acute 
hypoxic conditions. Antihypoxic effect severity and 
therapeutic effect range depends on the substance and 
a type of hypoxia. 
On AHBH and AHwHc models acyzol, cobazol, 
tetravim, vim, allim-1, allim-2, pilim-1, pilim-2, 
ALL, CoALL, BIS-N, BIS-3 were effective in 1–250 
mg/kg dose range i/p, increasing animal survival by 
17–176%, but g-4, g-5, g-6, g-7 and g-8 substances 
were ineffective. In conditions of AHeH acyzol, 
cobazol, tetravim, allim-1, allim-2, pilim-1, CoALL, 
BIS-N, g-4 showed the protective effect in 10–250 
mg/kg dose range, i/p. Mice lifespan was increased 
by 19–92%. Vim, pilim-2, ALL, g-5, g-6, g-7, g-8 
and BIS-3 were ineffective. In conditions of AHtH 
cobazol, tetravim, allim-1, allim-2, CoALL, g-6 
showed antihypoxic effect in 5–250 mg/kg dose 
range, i/p by 19–144%. Acyzol, vim, ALL, g-4, g-5, 
g-7, g-8, BIS-3 and BIS-N didn’t have any protective 
effect, and pilim-1 and pilim-2 in 25 mg/kg and 50 
mg/kg i/p doses demonstrated an oppressive effect. 
Allim-1, allim-2, pilim-1 and pilim-2 antihypoxic 
results confirm the literature data [59-63]. 
Two of seventeen compounds showed the highest 
antihypoxic effect on 4 hypoxic models. So, the iron 
complex (tetravim) increased the mice lifespan by  
21–127% in 5–250 mg/kg dose range on 4 acute 
hypoxic models, and the cobalt complex (CoALL) 
increased the lifespan by 17–181% in 10–150 mg/kg 
dose range, compared with the control group. The 
intensity and the effective dose range is higher, than the 
ones of the control drugs: etomerzole, mexidolum, 
nooglutyl and hypoxen (table 2) 
Tetravim and CoALL antihypoxic effect was 
also shown on 4 acute hypoxia models, when they 
were injected i/g in a high dose range (50–1200 
mg/kg and 25–300 mg/kg respectively). The mice 
lifespan was increased by 23–134% and 17–169%, 
respectively, compared with the control group.  
In this way, the broad spectrum of tetravim and 
CoALL activity on hypoxic models of different 
origin in the different ways of administration lets us 
speak about the universality of their antihypoxic 
effect and recommend their further research as 
potential antihypoxants. 
Effect of the coadministration of the  
N-alkenylimidazole metal complexes with 
different pharmacological classes drugs on the 
mice lifespan during acute hypoxia. Studying of the 
antihypoxic activity of the zinc (acyzol), cobalt 
(cobazol, CoALL) and iron (tetravim) complexes in 
combination with different pharmacological classes 
drugs can expand application field of the compounds 
and help to avoid potential side effects of acyzol and 
cobazol. It can also provide benefit in further 
investigation of tetravim and CoALL for their 
introduction into clinical practice. 
We used acyzol, cobazol and CoALL at a dose 
of 25 mg/kg, and tetravim at a dose of 50 mg/kg. This 
doses correspond to the intermediate value among 
dosages which demonstrate antihypoxic activity and 
statistically significant increase mice lifespan after 
hypoxia of the different origin. 
Acyzol, cobazol, CoALL and tetravim in 
combination with the different pharmacological 
classes drugs showed synergetic and antagonistic 
effects, which led to the increase and decrease of the 
N-alkenylimidazole derivatives antihypoxic activity. 
The effect of the compounds should be further 
investigated (table 3). 
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Table 3 
Effect of the co-administration of the N-alkenylimidazole metal complexes with different pharmacological classes drugs 
on the mice lifespan during acute hypoxia 
Substance, drug 
Dose, mg/kg, 
i/p 
Hypoxic model 
AHBH AHwHc AHeH AHtH 
Metaprot 50 111±10 92±4 121±5* 108±13 
Acyzol 50 222±9* 200±8* 160±7* 97±7 
Acyzol+ metaprot 50+50 167±9* 167±9* 130±4* 102±14 
Cobazol 50 200±10* 143±4* 130±7* 142±9* 
Cobazol+metaprot 50+50 184±6* 140±7* 117±3* 140±4* 
CoALL 25 254±9* 120±6* 135±5* 139±11* 
CoALL+ metaprot 25+50 189±3* 131±4* 133±7* 154±8* 
Tetravim 50 190±5* 195±6* 123±5* 135±9* 
Tetravim+ metaprot 50+50 169±10* 175±7* 149±5* 151±9* 
Mexidol 100 105±10 120±6* 119±4* 104±7 
Acyzol 50 216±14* 195±2* 170±5* 108±5 
Acyzol+mexidol 50+100 211±9* 190±4* 157±7* 100±5 
Cobazol 50 193±13* 139±4* 135±6* 142±8* 
Cobazol+ mexidol 50+100 202±13* 149±5* 128±5* 146±5* 
CoALL 25 259±11* 116±4* 135±6* 139±7* 
CoALL+mexidol 25+100 272±6* 123±5* 150±6* 143±7* 
Tetravim 50 184±13* 199±4* 123±4* 147±8* 
Tetravim+mexidol 50+100 240±6* 180±4* 140±4* 155±6* 
Aktovegin 40 108±2 95±8 112±4 105±7 
Acyzol 50 220±11* 198±5* 159±3* 97±8 
Аcyzol+aktovegin 50+40 166±10* 175±4* 131±6* 102±8 
Cobazol 50 190±7* 140±5* 136±4* 137±4* 
Cobazol+aktovegin 50+40 169±13* 144±5* 129±6* 145±3* 
CoALL 25 253±10* 118±5* 133±10* 117±9* 
CoALL+aktovegin 25+40 198±12* 119±2* 138±9* 119±10* 
Тetravim 50 196±9* 194±6* 128±4* 139±8* 
Теtravim+aktovegin 50+40 160±9* 191±5* 140±5* 141±7* 
Inosin 200 91±16 98±7 93±4 85±10 
Acyzol 50 199±13* 191±5* 160±3* 97±9 
Аcyzol+inosin 50+200 96±13 102±6 98±8 134±6* 
Cobazol 50 182±8* 136±5* 141±4* 131±5* 
Cobazol+inosin 50+200 110±10 96±7 111±9 176±2* 
CoALL 25 245±15* 121±3* 133±11* 141±8* 
CoALL+inosin  25+200 109±3 109±3 88±15 170±8* 
Теtravim 50 190±9* 186±3* 133±4* 139±10* 
Теtravim+inosin 50+200 98±14 101±8 109±7 147±8* 
Pikamilon 20 110±12 101±7 109±7 130±8* 
Аcyzol 50 192±11* 197±6* 151±3* 108±9 
Аcyzol+ pikamilon 50+20 99±9 103±7 94±10 92±10 
Cobazol 50 173±5* 141±4* 140±2* 133±5* 
Cobazol+pikamilon 50+20 107±7 97±7 104±7 163±6* 
CoALL 25 214±11* 122±2* 131±6* 141±7* 
CoALL+pikamilon 25+20 92±14 109±3 98±10 156±11* 
Теtravim 50 197±8* 173±3* 131±2* 141±12* 
Теtravim+pikamilon 50+20 107±12 98±5 113±4 156±11* 
АСК 125 105±18 95±8 80±6* 88±9* 
Аcyzol 50 198±10* 192±4* 163±4* 97±8 
Аcyzol+АSA 50+125 105±18 105±7 71±12* 97±8 
Cobazol 50 188±8* 136±5* 142±4* 131±5* 
Cobazol+АSA 50+125 110±10 96±7 87±9* 176±2* 
CoALL 25 253±10* 121±4* 139±10* 141±8* 
CoALL+АSA 25+125 106±14 109±3 102±14 188±7* 
Тetravim 50 190±9* 186±5* 128±4* 139±10* 
Теtravim+АSA 50+125 98±14 101±7 83±9* 105±11 
 
Notice.* – Significant differences compared with control animals at p < 0.05. Data are expressed as M ± m.  
M – arithmetic mean as % relative to the control group (100%); m – standard error of the mean as % relative to the arithmetic 
mean.  
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Metaprot in combination with tetravim showed 
summarized antihypoxic effect on AHeH model, 
while CoALL in combination with tetravim 
demonstrated slightly potentiated effect on AHtH 
model. Combination of mexidol, CoAll and tetravim 
had weak potentiating effect of the metal complexes 
protective properties on AHBH model and 
summarized effect on AHeH model. Other metaprot 
or mexidol combinations with N-alkenylimidazole 
derivatives were ineffective on the different acute 
hypoxia models. Actovegin in combination with 
acyzol, cobazol or CoALL was inefficient and didn’t 
affect or reduced metal complexes antihypoxic 
activity. Use of the inosine combined with the  
N-alkenylimidazole derivatives led to potentiation of 
the antihupoxic activity on AHtH model and was 
ineffective on the other models. Picamilonum 
administration and its combination with cobazol, 
CoALL and tetravim potentiated antihypoxic activity 
of the N-alkenylimidazole derivatives on AHtH. 
Use of ACA with cobazol or CoALL led to the 
potentiation of the antihypoxic activity of the cobalt 
complexes on AHtH. Other combinations on the 
other models didn’t affect or reduced  
N-alkenylimidazole derivatives protective activity, 
likely due to the inhibition of the cellular respiration 
in the mitochondrias [64]. 
 
Тable 4 
Effect of the N-alkenylimidazole metal complex derivatives and officinal drugs on the mice physical performance  
in normal and complicated conditions of hypoxia 
 
Substance, drug 
Dose, mg/kg, i/p 
1 2,5 5 10 25 50 100 200 
Run in normal condition 
Аcyzol 96±6 89±10 92±7 96±10 90±9 - - - 
Cobazol 120±6* 161±8* 146±6* 122±5* 74±6* - - - 
CoALL 98±9 90±12 91±8 87±12 69±9* - - - 
Теtravim 96±12 90±8 91±10 90±6 88±10 84±5 - - 
Аcyzol+cobazol 132±5* 153±8* 182±9* 123±4* - - - - 
Metaprot - - - - 112±4 131±4* 135±2* 106±2 
Bromantan - - - - 115±6 128±3* 126±3* 113±4 
Etomerzol - - - - - 104±7 - - 
Swimming in normal condition  
Аcyzol 94±11 110±10 109±10 106±7 96±8 - - - 
Cobazol 124±8* 175±9* 154±9* 112±7 79±10* - - - 
CoALL 109±11 99±9 101±10 93±8 65±10* - - - 
Теtravim 98±12 95±14 104±7 101±7 94±10 91±8 - - 
Аcyzol+cobazol 136±6* 186±6* 158±8* 119±8 - - - - 
Metaprot - - - - 89±5 124±5* 101±6 108±6 
Bromantan - - - - 111±4 129±7* 122±3* 97±4 
Etomerzol - - - - - 95±9 - - 
Run in AHBH condition  
Аcyzol - - - - 149±5* - - - 
Cobazol 130±4* 143±4* 197±5* 128±5* 135±9* - - - 
CoALL - - - - 156±7* - - - 
Теtravim - - - - - 153±6* - - 
Аcyzol+cobazol 124±5* 132±9* 146±7* 189±3* - - - - 
Metaprot - - - - - 98±10 127±8* - 
Bromantan - - - - - 94±8 98±8 - 
Etomerzol - - - - - 94±8 - - 
Swimming in AHwHc condition  
Аcyzol - - - - 128±7* - - - 
Cobazol 108±6 102±8 104±13 97±8 120±5* - - - 
CoALL - - - - 128±7* - - - 
Теtravim - - - - - 133±8* - - 
Аcyzol+cobazol 116±4* 120±4* 98±7 108±9 - - - - 
Metaprot - - - - 90±8 111±6 93±8 - 
Bromantan - - - - 109±9 99±5 - - 
Etomerzol - - - - - 96±10 - - 
 
Notice.* – Significant differences compared to control animals at p < 0.05. Data are expressed as M ± m. M – arithmetic mean 
as % relative to the control group (100%); m – standard error of the mean as % relative to the arithmetic mean. 
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Pharmacological properties analysis of  
N-alkenylimidazole metal complex derivatives. 
The influence of CoALL and tetravim on physical 
activity in normal and hypoxic condition was studied 
in the experiments on laboratory animals (mice, rats, 
rabbits). The functions of CNS, liver, kidneys, 
oxidative and carbohydrate metabolisms, blood count 
indexes, blood microcirculation, oxygenation 
processes, Red-Ox potential were studied. The 
preference was given to these parameters because of 
their importance in maintaining homeostasis in 
conditions of acute hypoxia. The results were 
compared with the effect of acyzol and cobazol, 
which had already found their application in clinical 
practice. The study in comparison lets us estimate a 
full picture of the influence of the zinc, cobalt and 
ferric complexes on animal organism functions.  It 
will also help us to extend their clinical application, 
to suppose any contraindications and side-effects, and 
to judge about the mechanism of antihypoxic action. 
Physical performance in normal and 
complicated conditions. According to the table 4, in 
normal conditions physical performance of animals 
was decreased or not changed because of metal 
complexes used in active antihypotoxic doses.  
In lower doses (1–10 mg/kg) аcyzol, tetravim 
and CoALL showed no effect, but cobazol increased 
the duration of running by 20–61% and the duration 
of swimming by 24–75% (p <  0.05). The highest 
efficacy (up to 82%) was shown when cobazol and 
acyzol were used together. Indeed, combined 
injection of cobazol and acyzol in doses of 1; 2,5; 5; 
10 mg/kg increased the duration of the run in studied 
mice by 32, 53, 82, 23% and the duration of swiming 
by 36, 86, 58, 19% (p < 0.05). In conditions of 
AHBH and AHwHc test drugs showed actoprotecting 
effect, that overperformed metaprot, bromantan and 
etomerzol. Further studies of actoprotecting effect of 
N-alkenylimidazol derivatives and their combinations 
is an interesting subject. 
Central nervous system function. According to 
the results of CDRA-test, studied metal complexes 
did not show notable influence on CDRA of rats, but 
remarkably decreased the influence of AHBH on 
reflex lassitude and positive reaction generating to 
conditioned excitator, that proved the increasing 
resistance of the higher regions of animals CNS to 
acute hypoxia (fig. 3). 
 
 
 
 
Figure 3. The effect of derivatives of N-alkenylimidazole on CPRA on rats 
Notice.* – Significant differences compared to control animals at p < 0.05. Data are presented as % relative  
to the control group (100 %) 
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Noted, that with corazol injected, cobalt, ferric 
and zinc complexes reliably increased latent time of 
cramps and lifespan in studied mice compared to the 
control group. Considering that corazol increases 
brain demand in oxygen, the mechanism of 
anticonvulsant action of studied drugs could be 
established with their effect on cellular hypoxia and 
their capability to reduce neuronal oxygen 
consumption. 
Conducted ethological experiment showed, that 
in 1 hour after intraperitoneal administration of metal 
complexes, tendency of decreasing activeness was 
noticed in all experimental animals compared to the 
control group. Indeed, after CoALL, acyzol, cobazol 
(25 mg/kg) and tetravim (50 mg/kg) administration 
the depression of patterns in behavioral structure was 
noted, such as: «sniffing» by 35, 35, 40 and 24%; 
«movement on the spot» by 44, 48, 43 and 33%, 
«burrow» by 70, 69, 68 and 40%, «moving» by 71, 
64, 65 and 33% respectively. Volume of pattern 
«sitting» increased by 69, 83, 64 and 55% 
consequently. Patterns «grooming», «stand with 
support», «vertical stand», «defecation» were not 
observed (fig. 4). 
 
 
 
 
 
Figure 4. The effect of the N-alkenylimidazole derivatives on the volume and structure of behavior of rats in «open space» 
Notice. S – sniffing, M – moving, B – burrow, MoS – movement on the spot, S – sit, ER – emotional reactivity, EA – 
emotional anxiety, RRA – reference research activity, CM – coefficient mobility. 
Significant differences compared to the control animals at p < 0.05. Data are presented as % relative to the control 
group (100 %). 
 
 
Metal complexes derivatives were changing 
integral characteristics of individual animal behavior. 
Indeed, in 1 hour after CoALL, acyzol, cobazol and 
tetravim administration ER increased by 69, 83, 64 
and 55% respectively; EA, RRA and CM decreased 
by 44, 54, 49 and 40%, 47, 54, 49 and 28, 87, 45, 79 
and 58% respectively, compared to the control 
values. ER increase is a result of depressing effect of 
the test drugs on emotional and motional spheres of 
the CNS.  
Therefore, cobalt, iron and zinc complexes with 
N-alkenylimidazol intensify ability of the higher 
regions of animals CNS to resist acute hypoxia. 
Materials about depressing effect of the studied drugs 
on emotional and motional spheres of CNS received 
with trials could be considered as one of the possible 
mechanism of the antihypoxic action. Most possibly 
a few complementary mechanisms and not just one 
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mechanism form a basement of raising resistance of 
the CNS to hypoxia that was observed after metal 
complexes had been used, that seems to be an 
interesting subject to research. 
Liver function. In experiments on rabbits, 
CoALL and tetravim administration one hour before 
AHBH restored the increased level of glucose in 
blood after galactose loading, that proves the gain in 
carbohydrate liver function (fig. 5). 
  
 
 
 
 
Figure 5. The effect of CoALL (25 mg/kg), tetravim (50 mg/kg), AHBH and their combination on blood sugar in rabbits after 
intravenous administration of galactose (1 mg/kg) 
Notice. * – Significant differences compared to control animals at p < 0.05. Data are presented as % relative to the control 
group (100 %). 
 
 
Metal complex derivatives of CoALL, cobazol, 
tetravim, acyzol, AHBH and their combined action 
didn’t influence the concentration of total protein, 
albumins, globulins, cholesterol, triglycerides, direct 
and total bilirubin. 
In mice that were receiving CoALL and cobazol 
in dosage 25 mg/kg, concentration of ALT decreased 
by 43 and 28% respectively. Concentration of AST 
increased by 138 and 59% respectively compared to 
the control mice (table 5). 
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Table 5 
The effect of CoALL (25 mg/kg), tetravim (50 mg/kg), acyzol (25 mg/kg), cobazol (50 mg/kg),  
AHBH and combined on the activity of enzymes of blood serum of mice 
Substance and type 
influence 
Activity of enzyme, ЕD/l 
АSТ/АLТ 
ALT AST 
аbs. % p аbs. % p аbs. % 
Control 42.0±1.5 100 - 119.0±4.4 100 - 2.8 100 
AHBH 49.3±1.8 117 < 0.001 157.1±6.7 132 < 0.001 3.2 14 
CoALL 24.0±1.2 57 < 0.001 283.3±12.0 238 < 0.001 11.8 421 
Теtravim 40.7±1.8 97 > 0.05 122.4±4.4 103 > 0.05 3.0 107 
Аcyzol 44.2±2.3 105 > 0.05 126.4±6.4 106 > 0.05 2.9 104 
Cobazol 30.2±3.3 72 < 0.01 189.5±14.0 159 < 0.001 5.3 189 
CoALL+AHBH 23.2±3.2 55 < 0.001 133.1±9.5 111 > 0.05 5.7 204 
Теtravim+AHBH 10.1±3.3 24 < 0.001 42.0±4.1 35 < 0.001 4.2 150 
Аcyzol+AHBH 28.1±3.7 67 < 0.01 69.0±6.9 58 < 0.001 2.5 89 
Cobazol+AHBH 31.5±3.8 75 > 0.05 129.7±12.9 109 > 0.05 4.1 146 
 
 
In mice that were treated with tetravim and 
acyzol, concentrations of ALT and AST were equal 
to the control group. In case of cobalt compounds 
administration one hour before AHBH concentration 
of AST was equal to the control value and was 
decreasing when using acyzol and tetravim, the level 
of ALT was decreased. 
High activity of AST when ALT is decreased 
could be a sign of suppression of peripheral 
metabolic reactions with multiple crossings and 
stimulation of central routs of catabolism close to 
CTA. AST/ALT ratio, determined after cobazol 
administration to mice were relatively significantly 
higher than control, that indicates an activation of 
central branches of catabolism, geared towards power 
supply by means of oxidizing organic substances, 
increase of substrate supply  in CTA and more 
efficient energy metabolism. 
 Mice hexenal sleep duration after the treatment 
with acyzol, cobazol, CoALL (25 mg/kg) and 
tetravim (50 mg/kg) didn’t change, so the liver detox 
function wasn’t disrupted. 
Therefore, the test compounds didn’t affect liver 
protein, lipid metabolism, pigmentary and detox 
function. Carbohydrate metabolism improvement 
after tetravim’ and CoALL administration, the 
elimination of hypoxia negative influence on 
carbohydrate metabolism and the change of AST and 
ALT enzymes after CoALL administration could be 
one of the supposed mechanisms of its action. 
In researched doses, CoALL and tetravim didn’t 
change kidneys nitrogen excretion and diuretic 
functions, and also urine physicochemical 
characteristics. 
The results of the research of 
electrocardiography dynamic also didn’t reveal any 
statistically significant changes, compared with the 
control group. 
Analysis of the ferric and cobalt complexes of 
the N-alkenylimidazole derivatives antihypoxic 
activity mechanism. Possible antihypoxic 
mechanism of the metal complex compounds CoALL 
and tetravim could be attributed to a few reasons, the 
main of which are the following: 
– cell Red-Ox potential regulation during the 
hypoxy; 
– energy consumption optimization under the 
oxygen deficiency conditions; 
– blood microcirculation improvement; 
– oxygen supply optimization due to cobalt 
influence on the carbonic anhydrase;   
– cobalt activation of the endogenous 
erythropoietin synthesis, gain of the erythropoeisis 
and HIF-1 stabilization; 
Other reasons of the test compounds antihypoxic 
activity could not be excluded, which proves the need 
for the further investigation of the protective activity 
under the oxygen starvation conditions. 
To clarify possible antihypoxic activity 
mechanism of the new N-alkenylimidazole 
derivatives CoALL and tetravim blood morphology 
and biochemistry, oxidative and carbohydrate 
metabolism, microcirculation intensity and Red-ox 
potential regulation were evaluated on the 
experimental animal models. 
Oxidative metabolism. Oxidative processes 
intensity and their association with the 
phosphorylation could be estimated by the oxygen 
consumption and body temperature.  
Oxygen consumption significantly decreased by 
38 and 40% in an hour after administration of 
CoALL and tetravim at the dose of 25 mg/kg and  
50 mg/kg respectively in comparison with initial 
level and restored initial values at 24 hours.  
Decoupler of the oxidative phosphorylation  
2,4-dinitrophenol (2,4-DNF) administration at the 
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dose of 5 mg/kg increased mice oxygen consumption 
in a hour after administration on 38% (p < 0.05). 
Coadministration of 2,4-DNF (5 mg/kg) with CoALL 
(25 mg/kg) or tetravim (50 mg/kg) significantly 
decreased by 16 and 18% oxygen consumption in a 1 
hour respectively in comparison with initial level and 
raised back to the initial values at 24 hours (fig. 6). 
 
 
Figure 6. Effect of CoALL (25 mg/kg), tetravim (50 mg/kg), 2,4-DNP (5 mg/kg)  
and combinations thereof on mice oxygen consumption (n = 10) 
Notice. * – Significant difference (р ˂ 0.05). Data are referred to the control value, which was taken as 100%. 
 
 
So, CoALL and tetravim decreased oxygen 
consumption and reduced 2,4-DNF adverse influence 
on it.  
Rectal temperature of the test animals decreased 
by 10 and 7% (p < 0.05) an hour since the CoALL 
and tetravim administration, respectively, in 
comparison with the control values. In an hour after 
2,4-DNF administration (5 mg/kg) temperature rose 
up to 39,6°C, which was 7% above the control 
values, and only 24 hours after administration 
temperature came back to the initial level (fig. 7).  
Coadministration of CoALL, tetravim and 
 2,4-DNF at the same doses did not affect rectal 
temperature in the both time points.  
N-alkenylimidazole derivatives effect on the 
oxidative metabolism could be attributed to their 
ability to transform aerobic respiration into 
anaerobic, which decreases oxygen demand. Gas 
exchange restore in 24 hours since compound 
administration could happen because of its excretion 
in this period of time and/or formation of the 
metabolites which doesn’t affect oxygen 
consumption. The more economy energy uptake 
could be explained by the compound interference into 
oxidative phosphorylation coupling mechanism in 
mitochondria, which decreases decoupling of this 
processes.   
Oxygen consumption and rectal temperature 
restore analysis after 20 min of simulation of the 
presence at a height of 7500 m showed decreased 
oxygen consumption after hypoxia in control animals 
for 60 min, which indicates that mitochondrial 
respiratory function is disturbed (table 6). 
Animals from the test group did not demonstrate 
decrease in the oxygen consumption after hypoxia, 
which could be the result of the CoALL and tetravim 
beneficial effect on mitochondria structure and 
function under the oxygen deficiency conditions. the 
control group. Body temperature of mice treated with 
CoALL and tetravim did not decrease after the 
simulation. Influence on oxidation and 
phosphorylation coupling and mitochondria structure 
and function maintenance during the hypoxia may 
play the main role in the antihypoxic mechanism of 
the test compounds. 
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Figure 7. Effect of CoALL (25 mg/kg), tetravim (50 mg/kg), 2,4-DNP (5 mg/kg) and combinations thereof  
on mice rectal temperature (n = 10) 
Notice. * – Significant difference (р ˂ 0.05). Data are referred to the control value, which was taken as 100% 
 
Тable 6  
The effect of CoALL (25 mg/kg) and tetravim (50 mg/kg) on the oxygen consumption 
 of mice in the early after hypoxic period (n = 10) 
Chemical compound 
Basic data 
Since 60 min after leading 
chemical compounds 
Since 5 min after sinking 
with the «height» 
Since 60 min after sinking 
with the «height» 
Oxygen consumption, ml/мin/100 g of body weight 
М ± m М ± m М ± m М ± m 
Control 5.0 ± 0.2 5.0 ± 0.2 2.5 ± 0.2* 2.8 ± 0.3* 
CoALL 5.0 ± 0.2 3.1 ± 0.3* 5.1 ± 0.4 5.2 ± 0.3 
Теtravim 5.0 ± 0.2 3.0 ± 0.3* 4.9 ± 0.3 5.0 ± 0.4 
Rectal temperature, ºС 
 М ± m М ± m М ± m М ± m 
Control 37.0 ± 0.2 36.9 ± 0.2 34.0 ± 0.5* 34.3 ± 0.5* 
CoALL 37.0 ± 0.4 33.5 ± 0.1* 33.7 ± 0.6* 33.9 ± 0.4* 
Теtravim 37.0 ± 0.1 34.5 ± 0.3* 34.8 ± 0.3* 35.1 ± 0.5* 
Notice.* – Significant differences compared to control animals at p < 0.05. Data are shown as M ± m. 
 
The data showed, that simulation of the presence at  
Glucose blood level. Glucose content decreased 
by 25% with comparison to control level in the 
AHBH conditions caused by the simulation of the 
presence of the animal at a height of 7500 m for 20 
min. Glucose blood level of mice treated with the 
CoALL (25 mg/kg) and tetravim (50 mg/kg) did not 
change. Glucose blood level of the animals treated 
with the metal complexes compounds an hour before 
hypoxia performance was relatively similar to the 
control group values. Increase in glucose content was 
28 and 40% in comparison with the animals, which 
were not treated with CoALL and tetravim, 
respectively, before AHBH exposure. Thus, test 
compounds did not affect glucose blood level, but 
prevented hypoglycemia, caused by AHBH. 
Complete blood count. Single dosing of the 
CoALL (25 mg/kg) and tetravim (50 mg/kg) had 
different influence on hemogramm parameters. 
Hematocrit, hemoglobin and formed elements levels 
in mice blood increased significantly in an hour after 
CoALL administration. The amount of the 
leukocytes, lymphocytes, monocytes, granulocytes, 
thrombocytes and erythrocytes increased by 97, 88, 
90, 180, 29, and 30% respectively. Hematocrit and 
hemoglobin level significantly increased by 27 and 
28%, respectively, in comparison to the control 
values. Tetravim administration did not affect 
morphological parameters, hemoglobin level or 
hematocrit (table 7).  
80
85
90
95
100
105
110
Control 2,4-DNF CoALL 25 mg/kg CoALL 25 mg/kg+2,4-
DNF 
Теtravim 50 mg/kg Теtravim 50 
mg/kg+2,4-DNF 
100 
107* 
90* 
99 
93* 
99 99 99 99 
100 
99 
after 1 hour after 24 hour
 N-alkenylimidazole metal complex derivatives as effective agents for the hypoxic conditions / S.A. 
Shakhmardanova, P.A. Galenko-Yaroshevsky // Research result: pharmacology and clinical 
pharmacology. – 2017. – Vol. 3, №1 – P. 49-72. 
66 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
Table 7 
The effect of CoALL (25 mg/kg), tetravim (50 mg/kg), AHBH and combined on the hemogram 
Index, unit Control 
AHBH CoALL AHBH+CoALL Теtravim AHBH+tеtravim 
аbs. % аbs. % аbs. % аbs. % аbs. % 
Leucocytes, х109 
g/l 
5.8±0.3 5.9±1.1 102 11.4±1.1 197* 7.9±0.7 136* 6.5±0.2 112 6.5±0.2 152* 
Lymphocytes, х109 
g/l 
4.3±0.5 4.4±0.3 102 8.1±0.8 188* 5.0±0.3 116 4.9±0.5 114 4.9±0.5 116 
Мonocytes, х109 
g/l 
1.0±0.1 0.9±0.1   90 1.9±0.2 190* 1.7±0.4 170* 1.1±0.1 110 1.1±0.1 210* 
Granulocytes, х109 
g/l 
0.5±0.1 0.6±0.1 120 1.4±0.1 280* 1.2±0.3 240* 0.5±0.1 100 0.5±0.1 340* 
Erythrocytes, х1012 
g/l 
5.6±0.5 7.1±0.3 127* 7.3±0.3 130* 5.9±0.2 105 6.1±0.3 109 6.1±0.3 100 
Hemoglobin, g/l 131.0±3.9 152.0±1.2 116* 166.0±5.8 127* 135.0±7.4 103 125.0±6.7   96 125.0±6.7 110 
Hematocrit, % 30.2±2.5 34.8±0.2 115* 38.8±1.6 128* 32.9±1.2 109 28.8±3.0   95 28.8±3.0   99 
Thrombocytes, 
х109 g/l 
375.0±28.0 338.0±19.0   90 485.0±19.0 129* 405.0±25.0 108 338.0±23.0   90 338.0±23.0 108 
Notice.* – Significant differences compared to the control animals at p < 0.05. The data are presented as M ± m.  
 
 
 
 
AHBH, induced by the presence for 20 min in 
vacuum chamber, simulating conditions at a height of 
7500 m, significantly increased erythrocyte and 
hemoglobin levels, and hematocrit on 27, 16 and 
15%, respectively compared to the control animals. 
Neither thrombocyte nor leukocyte  parameters had 
any significant differences. 
Mice treated with CoALL one hour before the 
hypoxia exposure had the same erythrocyte and 
hemoglobin levels, and hematocrit as at the 
beginning of the experiment. This results could be 
attributed to the erythrocyte level regulation, based 
on the feedback principle. Hypoxia activates 
erythropoietin synthesis, which in turns  affect bone 
marrow and stimulate erythropoiesis. Increase of the 
amount of the erythrocytes enhance oxygen supply 
and reduces the degree of the hypoxia, which leads to 
inhibition of the erythropoietin synthesis [65]. 
CoALL and AHBH together increased the levels of 
the leukocytes, monocytes and granulocytes on 36, 
70 and 140% respectively in comparison to the 
control levels. The lymphocytes counts did not differ 
from the initial values. 
It is known, that cobazol has stimulating effect on 
hemopoiesis [29]. Specific character of this effect is its 
targeting on increase of erythropoiesis rate and the 
amount of the leukocytes and thrombocytes. 
Immunomodulating effect of the cobazol is confirmed 
by the persistent increase of the lymphocytes amount 
and neutrophil phagocyte activity. 
Experiments showed, that cobazol effect was 
implemented through the hystotoxic hypoxia, caused 
in mesangial cells of the renal glomeruli, which 
resulted in the raise of the cAMP and cGMP levels 
and activation of the lysosomal enzymes of the 
erythropoietic fraction, which in turns increase the 
erythropoietin blood level [43]. Since CoALL and 
cobazol are analogous, it could be proposed that they 
share the hemostimulating mechanism. 
So, in our experiments ferric complex compound 
tetravim did not affect blood cells level, hemoglobin 
concentration and hematocrit, while the cobalt 
complex CoALL increased all the mice hemogramm 
parameters. The increase of the erythrocyte and 
hemoglobin levels, and hematocrit caused by the 
CoALL administration could be the key point of its 
antihypoxic activity. 
Microcirculation system. Microcirculatory 
bloodstream is the key point of the connection of the 
local and integral structural-functional homeostasis 
regulation systems, which provide energy substrate and 
oxygen supply at the appropriate level to the cell 
metabolic rate. By means of blood stream inner 
processes of the cell Red-Ox status control combined 
with homeostasis control through the changes in general 
and local bloodflow [65]. That is why microcirculation 
disorder, independently of the origin, leads to the cell 
hypoxia and disturbance in redox processes. 
It is known that the vascular tone control 
mechanism is based on reactive oxygen species [66]. 
At the same time, hypoxic conditions that affect 
tissue energetics usually result in hemodynamic 
disorders in the microcirculatory bloodstream [67]. 
Vasoactive and toxic metabolites release during 
the hypoxia affects bloodstream and leads to 
microcirculation disorders progression. It is known, that 
antihypoxic activity of the different drugs targets the 
microcirculation improvement (mexidol, actovegin et 
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al.). That is why it is important to investigate the effect 
of the new compounds with the significant antihypoxic 
activity on the microcirculation. 
To evaluate the metal complexes compounds 
CoALL and tetravim influence on the 
microcirculation state, we tested their effect on 
microhaemodynamics and tissue oxygenation. 
Microhaemodynamics. We estimated statistical 
parameters of the perfusion value, and this allows to 
calculate tissue perfusion level (TP) in perfusion 
units (p.u.), the mean square deviation, characterizing 
the temporal variability of the erythrocyte flow (σ or 
flax, p.u.), significant for assessing the 
microcirculation state and maintenance of its 
regulation mechanisms, as well as the ratio between 
variability of perfusion (flax) and average perfusion 
(TP), expressed in the variation coefficient (Kv) – the 
index of vasomotor activity of the microvessels. 
TP decreased approximately 4-fold after AHBH 
exposure, possibly, due to bloodstream redistribution 
(more efficient in the vital organs and less efficient in 
skin capillaries) and increases of the erythrocyte and 
thrombocytes aggregation activity and whole blood 
and plasma viscosity. Flax level decreased by 26%, 
which resulted in reduction of the oxygen return. Kv, 
characterizing vasomotor activity of the 
microvessels, increased by the 112%, which could be 
explained by the catecholamine and other vasoactive 
compounds production during acute hypoxia. 
TP was 18,4±1,9 p.u. an hour after the CoALL 
administration, that was 38% higher than control 
level. Flax level increased by 65%, Kv decreased by 
25% compared to the control values. CoALL 
administration an hour before the AHBH exposure 
decreased negative influence of the acute hypoxia on 
microcirculation. TP was similar to control values, 
and Kv and flax level were higher than in control 
group by 46 и 86% respectively.  
Tetravim affected microcirculation less than 
CoALL in the same conditions. TP increased 
significantly by 28% one hour after the compound 
administration at the dose of 50 mg/kg. At the same 
time Kv decreased by 40%, and flax level was 
relatively similar to the control values. Animals 
treated with tetravim one hour before the AHBH 
exposure demonstrated flax and Kv increase by 65 
and 56% respectively, and TP was similar to the 
control values (table 8).  
Table 8 
Effect of CoALL (25 mg/kg), tetravim (50 mg/kg), AHBH and their combination on microhaemodynamics (n=10) 
Substance and type influence 
TP σ Кv 
abs. % abs. % abs. % 
Control 13.3±1.4 100 3.7±0.5 100 37.8±9.2 100 
AHBH 3.1±0.8 23* 2.3±0.6 74* 80.2±7.9 212* 
CoALL 18.4±1.9 138* 6.1±0.5 165* 28.3±6.0 75* 
CoALL+AHBH 15.3±2.3 115 6.9±1.2 186* 55.1±5.2 146* 
Tetravim 17.0±1.2 128* 3.6±0.5 97 22.7±3.2 60* 
Tetravim+AHBH 13.7±1.0 103 6.1±0.9 165* 59.0±5.2 156* 
Notice. * – Significant differences compared to control animals at p < 0.05 
 
In general, the increase of the perfusion level 
after CoALL and tetravim administration indicates 
the ability of the compound to improve 
microcirculation. 
Tissue oxygenation. Optical tissue oxymetry 
showed that CoALL administration increased SO2 by 
23%. Oxygen utilization enhanced by the compound 
because of parameter U increased by 2,2-fold. Red-
Ox reaction level can be evaluated by the 40% 
decrease of Sm and 17% decrease of the oxygen 
concentration in the mixed blood of the 
microcirculatory bloodstream (table 9). 
Table 9 
Effect of CoALL (25 mg/kg), tetravim (50 mg/kg), AHBH and their combination on tissue oxygenation (n=10) 
Substance and type 
influence 
SO2 М Sm U 
abs. % abs. % abs. % abs. % 
Control 69.0±4.7 100 60.6±4.2 100 4.8±0.58 100 1.9±0.39 100 
AHBH 72.3±3.8 105 57.5±5.2 95 3.9±0.23 81* 0.9±0.21 47* 
CoALL 84.6±4.1 123* 50.3±4.8 83* 2.9±0.60 60* 4.2±0.81 221* 
CoALL+AHBH 75.1±4.3 109 52.0±2.3 86* 4.0±0.43 83* 3.7±0.62 195* 
Tetravim 75.0±7.1 109 58.0±2.5 96 4.7±0.30 98 2.0±0.70 105 
Tetravim+AHBH 65.8±5.3 95 62.0±3.1 102 5.0±0.90 104 2.0±0.45 105 
Notice. * – Significant differences compared to control animals at p < 0.05 
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Considering the fact that microcirculation is 
variable and adapt to the specific physiological 
demands of the tissue, the most meaningful 
characteristic is oxygen exchange parameter (EOE). 
Control animals had integral EOE value 25.5±1.2 a.u. 
After CoALL administration its value increased by 
85% compared to the control value (fig. 8). 
 
 
Figure 8. Effect of CoALL (25 mg/kg), tetravim (50 mg/kg), AHBH and their combination  
on erythrocyte concentration (Vr) and EOE (n =10) 
Notice. * – Significant difference (р ˂ 0.05). Data are referred to the control value, which was taken as 100%. 
 
Control animals had 6.2±0.3% of the 
erythrocytes in the test skin region. One hour after 
the CoALL administration erythrocyte content 
increased by 52% resulting in binding more oxygen. 
These data are consistent with the haemogramm data, 
which showed the increase of the erythrocyte amount 
in mice blood after the CoALL administration.  
After the perfusion restriction transcapillary 
exchange parameters in the skin of the test animals 
consistently decreased in AHBH model (Sm, U and 
EOE), because epidermal cells demonstrate enhance 
resistance to oxygen deficiency. Sm decreased by 19%, 
U by 53 and EOE by 46%. Vr increased by 15%. 
CoALL administration one hour before AHBH 
performance kept oxygen saturation at the control 
level. Perfusion oxygen parameter and oxygen 
concentration in mixed blood were lower than control 
values by 17 and 14%. U and EOE exceeded the 
control values by 95 and 50% respectively. 
Oxygen saturation in arterial and mixed blood, 
and specific consumption of the oxygen by the 
tissues were not affected by the tetravim 
administration. EOE value increased by 1,4-fold 
compared to the control values. As for the CoALL 
administration, the amount of the erythrocytes 
increased by 46% in the test skin region that more 
likely confirmed the Tetravim ability to mobilize the 
erythrocytes from the blood pool. 
So, multifunctional laser diagnostic complex 
«LAKK-M» for the full-scale study of the 
microcirculation tissue state allows to study 
microhaemodynamic parameters and oxygen 
transport under the influence of the biologically 
active compounds. All of the above changes in the 
microcirculation system caused by the  
N-alkenylimidazole derivatives enhanced tissue 
tolerance for the hypoxia. At the same time 
microhaemodynamics and EOE in tissues improved 
and erythrocyte content in microvascular blood flow 
increased. These data are useful for clinical science 
and partially explain antihypoxic mechanism of the 
test compounds. 
Red-Ox potential. The microcirculatory 
bloodstream closely associated with the redox 
systems of the cell, and provided the essential level 
of the oxygen and metabolites supply for the tissues 
[66]. Great changes of the Red-Ox potential always 
lead to the cell death activation. It is important to 
supply the cell with oxygen to maintain the redox 
balance, so it is obvious that the hypoxic states lead 
to a drastic change in the Red-Ox potential. 
In our studies, we used the emission of the 
respiratory chain enzymes NADH and FAD to 
determine the Red-Ox potential of the cell. In the 
recent years, physicochemical characteristics of 
pyridine nucleotides and FAD have been intensively 
studied in connection with the possibility of their use 
as intracellular markers of the activity of the cell 
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energy systems. It is known that the NAD and FAD 
fluorescence spectra characterize the energy «status» 
of the cell. Pyridine nucleotides fluoresce only in the 
reduced state (460–490 nm) and lose this ability after 
oxidation, while FAD, on the contrary, fluoresce only 
in the oxidized form (520–530 nm) and lose this 
property upon the transition to the reduced form. 
Transition from the rest state to the active 
energy metabolism is accompanied by the increase in 
the oxidized pyridine nucleotides (NAD
+
, NADP
+
), 
FAD and cytochromes concentration and 
corresponding decrease in the concentration of their 
reduced forms. The actively metabolizing tissues are 
characterized by spectra with approximately equal 
intensities of the emission of the reduced pyridine 
nucleotides and oxidized FAD. At the same time the 
rate of the respiratory chain electron transfer is as 
high as possible. 
The study of the CoALL and tetravim effect on 
the Red-Ox potential under AHBH conditions could 
be useful for investigating the possible mechanism of 
their antihypoxic effect. 
The FOCI and Red-Ox potential did not change 
1 hour after the administration of CoALL and 
tetravim to white outbred rats (table 10).  
Table 10 
The effect of tetravim (50 mg/kg), CoALL (25 mg/kg), AHBH and their combination on FOCI  
and Red-Ox potential (n=8) 
Substance and type 
influence 
АNADH Аflavins FOCI % Red-Ox  potential % 
Control 350±13.5 230±8.8 1.53±0.073 100 0.66±0.032 100 
AHBH 389±14.3 202±6.6 1.95±0.126 127* 0.53±0.034 80* 
CoALL 382±12.6 250±14.1 1.55±0.115 101 0.66±0.045 100 
CoALL+AHBH 370±8.6 256±16.9 1.46±0.081 96 0.69±0.042 105 
Tetravim 518±14.6 361±13.8 1.45±0.054 94 0.70±0.034 106 
Tetravim+AHBH 353±10.6 250±15.6 1.43±0.168 93 0.63±0.059 95 
Notice.* – Significant differences compared to control animals at p < 0.05. The data are presented as M ± m, where M 
is arithmetical mean and m is standard error of the mean. 
 
FOCI significantly increased by 27% Under 
AHBH conditions as a result of the increase in the 
fluorescence emission of reduced NADH and the 
decrease in the fluorescence emission of oxidized 
FAD. The Red-Ox potential decreased by 20% 
compared to the control values. The test substances 
administration 1 hour prior to AHBH exposure 
reduced the Red-Ox potential shift caused by the 
oxygen deficiency. 
Hypoxia, regardless of its etiology and symptoms, 
causes a cascade of damage to the multidimensional 
system, which leads to the disruption of the metabolic 
processes and Red-Ox systems imbalance. NADH 
concentration increase during the oxygen deficiency can 
lead to the switching of aerobic glycolysis to anaerobic. 
The decrease in the energy potential of cells, observed 
in this case, results in the fact that they not only lose the 
ability to perform their network functional duties in the 
organism, but they are not even able to provide their 
own vital activity, which inevitably leads to their death. 
The conducted studies indicate that the metal 
complex derivatives of N-alkenylimidazole tetravim 
and CoALL restore the Red-Ox potential shift 
induced by AHBH and may be useful as regulators of 
the Red-Ox state. 
Conclusions 
1. The strategic task of creating a new 
generation pathogenetic therapy drugs is the 
development of the drugs-regulators of the Red-Ox 
systems aimed at activation of the protective resource 
of the organism. Complexes of essential bioelements 
with corresponding ligands can claim the role of 
highly effective safe drugs. 
2. The tested metal complex derivatives of  
N-alkenyl-, N-propargylimidazoles and  
3-hydroxypyridine: acyzol, cobazol, vim, allym-1, 
allym-2, pilim-1, pilim-2, ALL, CoALL, BIS-N, BIS-
3, g-4, g-5, g-6, g-7 and g-8 belong to the class of 
moderately toxic compounds, which proves their 
safety. The iron complex of the vinylimidazole 
tetravim refers to low-toxic substances (LD50 for 
intraperitoneal administration is 1625 mg/kg, for 
intragastric administration 2100 mg/kg), and the 
copper complex of propenylimidazole, pilim-4, 
corresponds to the class of highly toxic compounds. 
3. Twelve of the 17 investigated metal complex 
derivatives of N-alkenyl-, N-propargylimidazoles and 
3-hydroxypyridine had an antihypoxic effect on 
models of the acute hypoxia of different origin. The 
degree of the antihypoxic effect and the range of 
therapeutic doses depends on the model of hypoxia 
and the compound. 
4. The antihypoxic effect of the cobalt complex 
named CoALL and iron complex named tetravim 
exceed the antihypoxic effect of the other compounds 
studied, as well as known antihypoxants and/or 
antioxidants: etomerzole, mexidol, nooglutyl and 
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hypoxen, in terms of the degree of the antihypoxic 
effect and the range of the effective doses in 4 types 
of hypoxia. 
5. The combined administration of CoALL, 
tetravim, acyzol and cobazol with drugs of different 
pharmacological classes results in synergy and 
antagonistic effects. 
6. CoALL and tetravim act as actoprotectors, 
increased resistance of the higher divisions of the 
animal CNS to the acute hypoxia, caused a 
depressing effect on the emotional and motor parts of 
the central nervous system, improved the 
carbohydrate function of the liver and eliminated the 
negative effect of hypoxia on carbohydrate 
metabolism; had no influence on protein and lipid 
metabolism, did not affect the function of the kidneys 
and heart under the conditions of AHBH or AHmHc. 
7. A possible mechanism of the antihypoxic 
effect of the test compounds could be attributed to the 
effect on coupling of oxidation and phosphorylation, 
maintenance of the mitochondria structure and 
functions in conditions of oxygen deficiency, 
elimination of the negative effect of hypoxia on 
carbohydrate metabolism, improvement of 
microcirculation and tissue oxygenation parameters 
and restore of the redox potential at hypoxia 
exposure. CoALL, probably, activates the key 
metabolism stages, which are responsible for energy 
supply by oxidizing organic substrates. The increase 
in the erythrocyte and hemoglobin levels and 
hematocrit could also be a factor of antihypoxic 
action of CoALL. 
8. Metal complexes CoALL and tetravim are 
promising for further development as drugs with 
antihypoxic, actoprotective and hemopoiesis 
stimulating activity. Red-Ox-regulating activity of 
metal complexes of the derivatives of 
N-alkenylimidazole offers the opportunities to 
construct new effective preparations of a wide 
spectrum of action on their basis. 
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